Bourla Writes His First PFE Check for $1M

ISB Research · Interesting · sent to Ultimate members August 12, 2026

Albert Bourla has run Pfizer for years without ever buying a share in the open market. Now he puts down $1,000,920 at $26.34, and two other insiders joined him inside the last month. That's a real cluster, and it lands while capital is quietly rotating into defensive healthcare. The 90-day track record on this name isn't pretty, so temper expectations past a month, but the setup here is clean with price above the 8-day and the trend pointing up across every timeframe. You could sell the September $26/$25 put spread for a $0.26 credit, about a 66% chance of keeping it at 35% return on risk, and it puts your entry under Bourla's price if you get assigned.

Ultimate members received this analysis in real time.